Explore the role of the therapeutic alliance between patients and intervention facilitators in PAT for MDD; a stronger therapeutic alliance was associated with more positive outcomes for patients.

How ketamine metabolite (2R,6R)-hydroxynorketamine effectively reduces anxiety-like behaviors associated with morphine withdrawal in mice by modulating neuronal excitability and potassium channel activity in the brain.

A single low dose of esketamine administered right after childbirth shows promise for postpartum depression, showing it could be a viable treatment option for new mothers showing signs of prenatal depression.

Ketamine shows better faster relief with fewer adverse events.

The retrospective study analyzed 68 treatment sessions involving 41 patients aged 5-21 years, predominantly girls with chronic migraine without aura. Patients were administered a median dose of 0.25 mg/kg/hr of IV ketamine over a median duration of 3 days.